Inhibition of PRMT5 moderately suppresses prostate cancer growth in vivo but enhances its response to immunotherapy. He Q, Zhang Y, Li W, Chen S, et al. Cancer Lett 2024;602:217214.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

He Q, Zhang Y, Li W, Chen S, et al. Inhibition of PRMT5 moderately suppresses prostate cancer growth in vivo but enhances its response to immunotherapy. Cancer Lett 2024;602:217214.
PMID: 39218291